XOMA exhibits a stark divergence between deterministic value metrics and market momentum. With a weak Piotroski F-Score of 3/9 and a current price ($37.89) trading significantly above its Graham Number ($15.24) and Intrinsic Value ($10.22), the stock is fundamentally overvalued by traditional standards. However, exceptional profit margins (60.81%) and strong YoY revenue growth (57.9%) support a growth narrative, further bolstered by a high analyst target of $65.75. The overall profile is that of a high-risk, high-reward royalty play with poor traditional health scores but strong operational efficiency.